Gozanertinib

N/A

Report date: 2026/04/30 20:00:20
NME

Base Information

Drug NameGozanertinib
Drug Alias NameDBPR-112ABT-101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR L858R inhibitorsEGFR T790M inhibitorsEpidermal growth factor receptor erbB1 inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1EGFR L858REGFR T790M +[5] 
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Health Research Institutes
China Registration ClassN/A

Develop Information

Active CompaniesAnbogen Therapeutics IncNational Health Research Institutes
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A